LivaNova PLC · NASDAQ:LIVN
LivaNova — Q3 2026 Earnings Presentation
30 slides from LivaNova's earnings presentation, Nov 4, 2026
Slide 1: Third-Quarter 2026 Earnings Update
November 4, 2026 Third-Quarter 2026 Earnings Update
Slide 2: Safe Harbor
Safe Harbor Certain statements in this presentation, other than statements of historical or current fact, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Exchange Act. These stateme
Slide 3: Intellectual Property, Trademarks, and Trade Names
Intellectual Property, Trademarks, and Trade Names This material may contain references to LivaNova's proprietary intellectual property, including among others: • Trademarks for LivaNova’s Neuromodulation systems, the VNS Therapy™ System, and LivaNova’s proprietary pulse generator products: Model 10
Slide 4: Contents
Contents 3Q26 Key Messages and Summary 3Q26 Financial Results 2026 Guidance and Assumptions Appendix 4
Slide 5: 3Q26 Highlights and Key Messages
3Q26 Highlights and Key Messages • Delivered 9.9% reported and 10.0% constant-currency(1) revenue growth with strength across all regions, reflecting strong Financial commercial execution and healthy demand for our Cardiopulmonary and Epilepsy technologies Results • Adjusted diluted earnings per sha
Slide 6: 3Q26 Summary
3Q26 Summary • Cardiopulmonary grew 10.9% with growth across all regions, driven by strong consumables demand and Essenz™ Revenue Perfusion System sales, as well as favorable realized price 10.0% Growth(1) • Neuromodulation grew 11.2% with double-digit growth across all regions, driven by higher vol
Slide 7: Financial Results
ly — Financial Results iS
Slide 8: 3Q26 Financial Summary
3Q26 Financial Summary 3Q25 3Q26 Net revenue increased 10.0% on a constant-currency basis; FX had a negligible year-over-year impact Net Revenue ($M) Adjusted Diluted EPS Adjusted FCF ($M) $62 $56 $1.23 $393 $1.11 $358 Adjusted Gross Profit % Adjusted SG&A % Adjusted R&D % Adjusted Operating Margin
Slide 9: 3Q26 Net Revenue
3Q26 Net Revenue Delivered 10.0% constant-currency(1) revenue growth Neuromodulation Vagus Nerve Stimulation Therapy (VNS Therapy) Cardiopulmonary • Drug-Resistant Epilepsy • Heart-lung machines • Difficult-to-Treat Depression 42% • Oxygenators $393M • Autotransfusion systems Proximal Hypoglossal Ne
Slide 10: 3Q26 Cardiopulmonary Revenue
3Q26 Cardiopulmonary Revenue(1) Drivers/Impacts Net Revenue ($M) 10.9% $225 $203 Cardiopulmonary revenue increased 10.9% led by double-digit growth in both Europe and the U.S. 88 81 Consumables revenue(2) grew low-double-digits, led by strength in oxygenators and perfusion tubing sets 57 50 HLM reve
Slide 11: 3Q26 Neuromodulation Revenue
3Q26 Neuromodulation Revenue(1) Drivers/Impacts Net Revenue ($M) 11.2% $166 $150 19 Neuromodulation revenue increased 11.2% with double-digit 17 17 growth across all regions driven by higher volume and favorable realized price 15 Epilepsy revenue grew 10.9% with U.S. Epilepsy revenue growth of 10.0%
Slide 12: 3Q26 Adjusted Segment Income and Operating Margin
3Q26 Adjusted Segment Income and Operating Margin(1) Strength of execution in core businesses enables planned investment in innovation pipeline $119M 3Q25 3Q26 $102M Cardiopulmonary 19.3% 21.6% Neuromodulation 41.9% 42.1% 70 Total Adjusted Segment Margin 28.9% 30.3% 63 Total Adjusted Operating Margi
Slide 13: Adjusted Free Cash Flow
Adjusted Free Cash Flow Delivered adjusted FCF of $56M driven by improving profitability, partially offset by increased planned capital investments and higher working capital investments Adjusted Free Cash Flow Reconciliation ($M) 1Q26 2Q26 3Q26 Net cash provided by operating activities $15.2 $66.6
Slide 14: 2026 Guidance
ly — 2026 Guidance iS
Slide 15: 2026 Guidance Tracking At or Above High End of Investor Day Commitments
2026 Guidance Tracking At or Above High End of Investor Day Commitments Raising full-year revenue(1) and adjusted diluted EPS(2) guidance, maintaining adjusted operating margin and adjusted FCF(3) guidance Prior Guidance Prior Guidance Prior Guidance Updated Guidance Investor Day Commitments As of F
Slide 16: Assumptions for 2026
Assumptions for 2026 • Cardiopulmonary revenue expected to grow 10.5 - 11.5% (versus 9.5 - 10.5% prior) REVENUE 9 - 10% • Epilepsy revenue expected to grow 8 - 9% (versus 7 - 8% prior) GROWTH(1) • DTD revenue expected to be ~$10M (consistent with prior guidance) • Adjusted operating margin of 20 - 2
Slide 17: Adjusted Diluted EPS Guidance Bridge: From Prior to Current Outlook
Adjusted Diluted EPS(1) Guidance Bridge: From Prior to Current Outlook $0.17 $0.03 $4.45 $4.35 ($0.10) At midpoint of At midpoint of $4.30 - $4.40 $4.40 - $4.50 range range As of August 5, 2026 Revenue and Operational Improvements Interest Income on Cash Reserved for Reinvestment into Business (2) A
Slide 18: OSA: Key Milestones and Expected Upcoming Catalysts
OSA: Key Milestones and Expected Upcoming Catalysts H1 2025 H2 2025 H1 2026 H2 2026 H1 2027 H2 2027 2030 aura6000 PMA (non-commercial) PMA filing approval PMA supplement $200-$400M submission Revenue in Commercial 2030 LMR & FMR Launch (MRI-compatible) (including PolySync) 18
Slide 19: Appendix
ndix Appe iy w
Slide 20: Glossary
Glossary CMS U.S. Centers for Medicare and Medicaid Services CPT Current Procedural Terminology DRE Drug-Resistant Epilepsy DTD Difficult-to-Treat Depression EPS Earnings Per Share FCF Free Cash Flow FMR Full Market Release FX Foreign Currency HGNS Hypoglossal Nerve Stimulation HLM Heart-Lung Machin
Slide 21: Segment Net Revenue Comparisons by Region
Segment Net Revenue Comparisons by Region Three Months Ended September 30, Constant-Currency ($M) 2026 2025 % Change % Change (1) Cardiopulmonary United States $80.4 $71.9 11.8 % 11.8 % Europe (2) 57.1 50.1 14.0 % 15.9 % Rest of World 87.8 81.2 8.1 % 7.1 % 225.3 203.2 10.9 % 10.9 % Neuromodulation U
Slide 22: Use of Non-GAAP Financial Measures
Use of Non-GAAP Financial Measures To supplement financial measures presented in accordance with generally accepted accounting principles in the United States (U.S. GAAP or GAAP), management has disclosed certain additional measures not presented in accordance with GAAP known as “non-GAAP financial
Slide 23: GAAP to Non-GAAP Reconciliations - Unaudited
GAAP to Non-GAAP Reconciliations - Unaudited RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES - UNAUDITED (In millions, except for per share amounts) Non-GAAP Adjustments Depreciation and Adjusted Three Months Ended GAAP Financial Amortization Financing Related Contingent Certain Legal & Share-
Slide 24: GAAP to Non-GAAP Reconciliations - Unaudited
GAAP to Non-GAAP Reconciliations - Unaudited RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES - UNAUDITED (In millions, except for per share amounts) Non-GAAP Adjustments Depreciation and Adjusted Three Months Ended GAAP Financial Amortization Investment Financing Related Contingent Certain Leg
Slide 25: GAAP to Non-GAAP Reconciliations - Unaudited
GAAP to Non-GAAP Reconciliations - Unaudited RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES - UNAUDITED (In millions, except for per share amounts) Non-GAAP Adjustments Depreciation and Adjusted Nine Months Ended GAAP Financial Amortization Investment Financing Related Contingent Certain Lega
Slide 26: GAAP to Non-GAAP Reconciliations - Unaudited
GAAP to Non-GAAP Reconciliations - Unaudited RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES - UNAUDITED (In millions, except for per share amounts) Non-GAAP Adjustments Depreciation and Adjusted Nine Months Ended GAAP Financial Restructuring Amortization Investment Financing Related Contingen
Slide 27: GAAP to Non-GAAP Reconciliations - Unaudited
GAAP to Non-GAAP Reconciliations - Unaudited RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES - UNAUDITED RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES - UNAUDITED (In millions) (In millions) Three Months Ended September 30, Last Twelve Months Ended Adjusted free cash flow reconciliatio
Slide 28: GAAP to Non-GAAP Reconciliations - Unaudited
GAAP to Non-GAAP Reconciliations - Unaudited RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES - UNAUDITED (In millions) Non-GAAP Adjustments Segment income Share-based Three Months Ended GAAP Depreciation and Contingent Certain Legal & Compensation Adjusted Financial September 30, 2026 Financia
Slide 29: GAAP to Non-GAAP Reconciliations - Unaudited
GAAP to Non-GAAP Reconciliations - Unaudited RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES - UNAUDITED (In millions) Non-GAAP Adjustments Segment income Share-based Nine Months Ended GAAP Depreciation and Contingent Certain Legal & Compensation Adjusted Financial September 30, 2026 Financial
Slide 30: Computation of Basic and Diluted Earnings (Loss) Per Share - Unaudited
Computation of Basic and Diluted Earnings (Loss) Per Share - Unaudited COMPUTATION OF BASIC AND DILUTED EARNINGS (LOSS) PER SHARE - UNAUDITED (In millions, except for per share amounts) Three Months Ended Nine Months Ended September 30, September 30, 2026 2025 2026 2025 Numerator: Net income (loss)